MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$6,356,000
EPS
-$0.55
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
0
-
0
0
Research and development
3,816,000
3,199,000
3,401,000
3,651,000
General and administrative
2,968,000
3,081,000
2,806,000
2,741,000
Total operating expenses
6,784,000
6,280,000
6,207,000
6,392,000
Loss from operations
-6,784,000
-
-6,207,000
-6,392,000
Interest expense
203,000
189,000
190,500*
6,000
Change in fair value of convertible promissory notes
-
-
0*
0
Change in fair value of warrants
-50,000
-104,000
-3,186,000
-1,044,000
Change in fair value of tranche liability
347,000
1,030,000
-
-
Loss on warrants expiration
-
-
-7,500*
724,000
Loss on extinguishment of financial commitment assets and contingent warrants, net
0
-1,616,000
-
-
Other income, net
234,000
60,000
-99,000
35,000
Total other income (expense), net
428,000
-611,000
2,889,000
1,797,000
Loss before income tax
-
-6,891,000
-3,331,500*
-
Provision for income taxes
-
7,000
4,500*
-
Net loss
-6,356,000
-6,898,000
-3,336,000
-4,595,000
Less net loss attributable to noncontrolling interest
0
0
0
-10,000
Net loss attributable to serina therapeutics, inc
-6,356,000
-6,898,000
-3,336,000
-4,585,000
Basic EPS
-0.55
-0.58
-0.313
-0.45
Diluted EPS
-0.55
-0.58
-0.313
-0.45
Basic Average Shares
16,385,000
12,047,000
10,661,000
10,339,000
Diluted Average Shares
16,385,000
12,047,000
10,661,000
10,339,000
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to serina...
-$6,356,000
(1.43%↑ Y/Y)
Change in fair value of
tranche liability
$347,000
Other income, net
$234,000
(244.12%↑ Y/Y)
Change in fair value of
warrants
-$50,000
(-105.23%↓ Y/Y)
Net loss
-$6,356,000
(1.64%↑ Y/Y)
Total other income
(expense), net
$428,000
(147.71%↑ Y/Y)
Interest expense
$203,000
(2155.56%↑ Y/Y)
Loss from operations
-$6,784,000
(-21.90%↓ Y/Y)
Total operating
expenses
$6,784,000
(19.12%↑ Y/Y)
Research and development
$3,816,000
(21.07%↑ Y/Y)
General and
administrative
$2,968,000
(16.71%↑ Y/Y)
Buy us a coffee
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc. (SER)